Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpoint Data included observations of immune activation with vaccine ...
PHILADELPHIA, Sept. 3 ERT (Nasdaq: ERES) has celebrated a significant milestone by completing its 150th thorough QT clinical Trial (TET). ERT provides full TET support to the biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback